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Research Trends

Stem cell
research:
Trends in and
perspectives
on the evolving
international
landscape
Alexander van Servellen & Ikuko Oba

Stem cell research is an exciting yet complex
and controversial science. The field holds
the potential to revolutionize the way human
diseases are treated, and many nations have
therefore invested heavily in stem cell research
and its applications. However, human stem
cell research is also controversial with many
ethical and regulatory questions that impact
a nation’s policies.
Elsevier recently partnered with EuroStemCell
and Kyoto University’s Institute for Integrated
Cell-Material Sciences (iCeMS) to study
publication trends in stem cell research.
The resulting paper was published online to
coincide with the World Stem Cell Summit in
San Diego on December 6th, 2013. The study
provides an overview of the stem cell research
field as a whole, with particular focus on
pluripotent stem cells.
Pluripotent stem cells are of particular
interest because they are undifferentiated
cells, which have the potential to differentiate
into virtually any cell type in the body (1;
see Figure 1). This property opens the door
to clinical applications such as cell and organ
replacement (2) and may accelerate drug
discovery, drug screening and toxicological
assessment. There are different kinds of
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pluripotent stem cells: embryonic stem cells
(ES) are sourced from a blastocyst (an early
embryo), and when sourced from human
blastocysts are called human embryonic
stem cells (hES), while induced pluripotent
stem cells (iPS) - which were only recently
discovered in 2006 by Shinya Yamanaka
and colleagues at Kyoto University - are
sourced from body cells, and then genetically
reprogrammed to become pluripotent. For
more detailed information on stem cells,
please refer to our study (3).
The document sets underlying our analyses
were created using keyword searches which
are provided in the methodology section of
our study, and were limited to articles, reviews
and conference proceedings. They include
primary research articles as well as other
publication types, such as reviews, papers on
policy and regulation, ethical considerations,
etcetera. In this article we briefly review
some key findings of our study, and expand
by having a closer look at the clinical theme
‘drug development’ using SciVal. We will also
examine the publication trends of China and
the United States specifically, to see whether
we can observe the impact of country level
policy decisions in the publication data.

Figure 1: Stem Cell types and characteristics.
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Publication output, growth and
field-weighted citation impact
Our study found that the overall corpus
of stem cell related papers shows a relatively
fast growth rate and citation impact.
Stem cell publications show a Compound
Annual Growth Rate (CAGR) of 7.0% from 2008
to 2012, which is more than twice as great as
the 2.9% CAGR for global publication output
on all topics in the same period. Stem cell
publications have a Field-Weighted Citation
Impact (FWCI) of approximately 1.5 throughout
the 2008-2012 period, which indicates that
stem cell papers, on average, received 50%
more citations than all other papers published
in related disciplines in that period. (Stem cells
and its subtypes are custom subject areas that
were created using keyword searches. Each
document set therefore includes publications
belonging to various disciplines of the All
Science Journal Classification).
Looking at specific types of stem cell research,
the emergence of the iPS cell field (first
publication in 2006) stands out. iPS cell papers
show explosive growth and the highest impact
of all types of stem cell research papers. The
FWCI of the iPS field was extremely high just
after its discovery, as might be expected of
an emerging field. The FWCI calculated at
the beginning of the period was based on
relatively low publication counts, which are
more subject to outlier effects than later datapoints, which are based on larger publication
volumes. The decline in FWCI (see Figure 3)
should not be interpreted as a decrease in
quality of research, rather it should be seen as
a natural and expected decline as publication
volume increases. Nonetheless, the 3,080 iPS
cell papers published between 2008-2012
have a FWCI of 2.93, which is almost 3 times
world level for all papers published in related
disciplines. That is strong evidence to support
the sustained recognition and importance of
the emerging field of iPS cell research.
We observed that hES cell publication output
peaked in 2010, and while ES cell research
overall shows a high publication volume, it is
predominantly represented by non-human
ES cell research (see Figure 2). The FWCI for ES
cell and hES cell publications also remained
relatively stable during the same period, at
around 1.8 times the world average for ES
cell publications, and over two times world
average for hES cell publications.
Clinical themes: Regenerative Medicine and
Drug Development
Our study also examined the extent to which
stem cell publications are aligned with the
societal goals of developing new treatments
for diseases, by analyzing the publications

Figure 2: Global publication count (1996-2012) and compound annual growth rate (CAGR)(2008-2012)
for all stem cells (Stem Cells), ES cells (all organisms; ESCs), hES cells (hESCs), and iPS cells (iPSCs).
Source: Scopus.

Figure 3: The FWCI of publications on stem cells overall and by cell type from 2008-2012. The pale blue
line represents the global average field-weighted citation impact for all publications in the various subject
areas, assigned to the journals in which stem cell papers are published. Source: Scopus.

for use of keywords related to two themes:
regenerative medicine and drug development.
The results show that more than half of all
stem cell publications do not use keywords
related to either theme (see Figure 4). Such
publications may be related to basic research
which addresses the fundamental biology
of stem cells. These specific themes may
also not be relevant to many clinical or
translational publications, e.g., those related
to hematopoietic stem cell transplantation
and cancer (translational research is scientific
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research that helps to make findings from
basic science useful for practical applications
that enhance human health and well-being).
It should also be noted that the search used to
compile the document set for overall stem cell
research was purposely broad, and can be
expected to include stem cell research of all
kinds, as well as research which refers to stem
cells in the title, abstract, and keywords, but
may not necessarily be considered “stem cell
research” per se.
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“Today, stem cell research is more about
understanding than about treating
illnesses. I do think it’s most important to
understand how our tissues are formed,
and how they get ill. I’d go further and
say that understanding stem cells
means understanding where we come
from. If we think of the embryonic stem
cells, they tell us a lot about how our
bodies develop from an embryo. They
provide a window on events which we
couldn’t otherwise observe.”
Elena Cattaneo,
Full Professor, Director, UniStem,
Center for Stem Cell Research,
University of Milan
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Figure 4: The percentage of stem cell papers published from 2008 to 2012 using keywords related to
“drug development,” “regenerative medicine,” or other by cell type. Source: Scopus.

It is not surprising to see that regenerative
medicine is significantly represented within
each type of stem cell research. Alongside
positive developments in stem cell biology,
regenerative medicine has enabled the
development of new biotechnologies that
promote self-repair and regeneration, such
as the construction of new tissues to improve
or restore the function of injured or destroyed
tissues and organs (4).
Drug development is represented by a
much smaller share of each type of stem
cell research. The fact that many more iPS
cell papers were related to drug development
(11%) compared to ES cells (4%) and stem
cells overall (2%) stands out. This may reflect
the particular potential that iPS cells hold
for the development of disease models,
personalized medicine, and drug toxicity
testing. iPS cells can be derived from
selected living individuals, including those
with inherited diseases and their unaffected
relatives, which could allow the screening
process to account for genetic differences
in response to potential new drugs.

Figure 5: Number of global publications related to “drug development” in ES, hES and iPS cell research
2006-2012. Source: Scopus.

Exploring Drug Development using SciVal
To expand on the analysis done in the study,
we used the new generation of SciVal to
examine stem cell papers related to drug
development by setting up the relevant
research fields using the same keywords
applied in our initial study. The results are
presented in Figure 5. The number of iPS
cell papers related to drug development
has clearly grown fast since the first iPS cell
paper was published in 2006, as it has since
surpassed the numbers of ES and hES cell
papers related to drug development.
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“I believe the biggest impact to date of iPS cell technology is not regenerative medicine,
but in making disease models, drug discovery, and toxicology testing…”
Shinya Yamanaka, Director Center for iPS Cell Research and Application (CiRA),
Kyoto University.
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World Publication Activity in Embryonic
Stem Cell (ES), Human Embryonic Stem cell
(hES) and induced Pluripotent Stem cell
research (iPS)

Figure 6: Global Stem Cell publications (top) and ES, hES and iPS cell publications (bottom), as a share of
total world output, from 1996-2012. Source: Scopus.

Stem cell research has provoked debate
regarding the ethics and regulation of the
research and resulting therapies. Initially these
discussions focused largely on the moral
status of the embryo. The discovery of iPS
cells raised the possibility that ES cell research
would no longer be necessary, thereby
circumventing the ethical issues present in
embryonic research. This has not been the
case, as the stem cell field continues to rely
both on ES and iPS cell research to progress
the understanding of pluripotency and
potential applications (5). Furthermore, iPS cell
research is not free of ethical considerations in
terms of how they may be used as well as the
question of tissue ownership. Looking at the
data, we see continued publications in ES and
hES, but do observe that the global volume
of iPS publications has surpassed the volume
of hES cell publications in 2010 (see Figure 6).
There also seems to be an overall slowing in
growth, and even a recent decrease in world
ES and hES cell publication output. These
findings should be interpreted with caution,
keeping in mind that our datasets represent
publications which use keywords related to
stem cell research, and not solely “stem cell
research papers”.
Stem Cells in China
We also examined the publication trends of
China and the United States specifically, to see
whether we can observe the impact of country
level policy decisions in the publication data.

Figure 7: China’s Stem Cell publications (top) and ES, hES and iPS cell publications (bottom), as a share of
total country output, from 1996-2012. Source: Scopus.
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China is a country which shows steady
growth in stem cell research supported by
its major funding initiatives. In 2001, the
Chinese Ministry of Science and Technology
(MOST) launched two independent stem
cell programs followed by a number of
funding initiatives intended to further promote
stem cell research, applications and public
awareness. At the same time, China has been
working to strengthen ethical guidelines and
regulations. In total, the national government’s
stem cell funding commitment is estimated at
more than 3 billion RMB (close to 500 million
USD) for the 5 year period from 2012 to 2016.
Confronted with the healthcare needs of a
rapidly aging population of nearly 1.4 billion,
the impetus behind much stem cell research,
so far, has understandably been clinical
translation and development (6).

4

van Servellen and Oba: Stem cell research: Trends in and perspectives on the evolving in

Research Trends Issue 36 March 2014

Page 10

Looking at the publication data from our
study, we see that stem cell publications have
grown from representing 0.2% of China’s total
publication output in 2001 to a peak of 0.82%
in 2008, followed by a marginal decline to
0.76% by 2012 (see Figure 7). As also observed
globally, China’s iPS cell publication output
surpassed hES cell publication output in 2010,
after which hES cell output shows fluctuation.
Science policy and Human Embryonic
Stem Cell (hES) research in the USA
The United States is an interesting case study
because, as reported in our study, they are
the world leader in stem cell research
considering that they produce the highest
absolute publication volume, as well as
high relative activity levels, indicating a high
focus on stem cell research, and show high
field-weighted citation impact. Yet, they have
had to grapple with the practical and ethical
dilemmas that are inherent in this field, and
changing views of different administrations,
as governments changed.
The result is a series of policy changes,
some of which limited federal funding for
hES cell research, while others loosened the
limitations. In Figure 8 we map such policies
along with the corresponding publication
output (relative to total country output). Despite
the restrictive policies between 2001 and
2009, the United States show steady output
growth, which has been supported through
individual, state and industry funding as well
as donations. We do observe changes in
hES cell publication output that coincide with
changes in regulation. While such changes
in publication output are probably not best
explained using a one factor model, these
findings are hardly surprising, as we expect
science policy to greatly impact scientific
activity. Such an analysis can provide insight
into the degree to which science policy has
indeed affected publication output.
Conclusion
In recent years, stem cell research has grown
remarkably, showing a growth rate more than
double the rate of world research publications
from 2008 to 2012. However, this increase
is not uniform across all stem cell research
areas. Our analysis showed that both ES
and hES fields have grown more slowly
than the stem cell field overall. In contrast,
iPS cell publications have shown explosive
growth, as would be expected of a new
and promising field of research, and iPS
cell publication volumes surpassed that of
hES cell publications in 2010. However, both
cell types continue to be highly active areas.

Published by Research Trends, 2007

Figure 8: USA’s hES publications as a share of total country output, from 1996-2012 and relevant US policy
decisions. Source: Scopus (and various sources for policy decisions).

Stem cell research has attracted considerable
attention within the scientific community:
stem cell publications overall are cited 50%
more than all other publications in related
disciplines, while ES cell publications are
cited twice the world rate, and iPS cell
publications nearly three times the world
rate. This high-growth, high-impact field
encompasses research across many cell
types, with a focus ranging from the most
fundamental to the clinical. Reflecting the
field’s ongoing development and clinical
promise, approximately half of all stem cell
publications are associated with regenerative
medicine or drug development, a trend that is
particularly pronounced in iPS cell research.
Stem cell research is developing fast, with
some experimental pluripotent stem cell
treatments already in clinical trials. Active
debates are underway to adapt regulatory
frameworks to address the specific challenges
of developing, standardizing, and distributing
cell-based therapies, while advances in
basic research continue to provide a fuller
understanding of how stem cells can be
safely and effectively used. Cell replacement
or transplantation therapies are not the only
application of stem cell research: already the
first steps are being taken towards use of cells
derived from pluripotent stem cells, in drug
discovery and testing. It is with great interest
and anticipation that we watch the further
development of this exciting field of science.
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